These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33931138)

  • 1. Role of histone acetyltransferase inhibitors in cancer therapy.
    Shanmugam MK; Dharmarajan A; Warrier S; Bishayee A; Kumar AP; Sethi G; Ahn KS
    Adv Protein Chem Struct Biol; 2021; 125():149-191. PubMed ID: 33931138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting cancer using KAT inhibitors to mimic lethal knockouts.
    Brown JA; Bourke E; Eriksson LA; Kerin MJ
    Biochem Soc Trans; 2016 Aug; 44(4):979-86. PubMed ID: 27528742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
    Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A bivalent role of TIP60 histone acetyl transferase in human cancer.
    Judes G; Rifaï K; Ngollo M; Daures M; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
    Epigenomics; 2015; 7(8):1351-63. PubMed ID: 26638912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KATs in cancer: functions and therapies.
    Farria A; Li W; Dent SY
    Oncogene; 2015 Sep; 34(38):4901-13. PubMed ID: 25659580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The GCN5: its biological functions and therapeutic potentials.
    Haque ME; Jakaria M; Akther M; Cho DY; Kim IS; Choi DK
    Clin Sci (Lond); 2021 Jan; 135(1):231-257. PubMed ID: 33443284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone modification therapy of cancer.
    Biancotto C; Frigè G; Minucci S
    Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases.
    Simon RP; Robaa D; Alhalabi Z; Sippl W; Jung M
    J Med Chem; 2016 Feb; 59(4):1249-70. PubMed ID: 26701186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patent spotlight: small-molecule lysine acetyltransferase inhibitors (KATi).
    Brown JA
    Pharm Pat Anal; 2020 Jan; 9(1):17-28. PubMed ID: 32008421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
    Mai A; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors.
    Marks PA; Richon VM; Miller T; Kelly WK
    Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone acetyl transferases as emerging drug targets.
    Dekker FJ; Haisma HJ
    Drug Discov Today; 2009 Oct; 14(19-20):942-8. PubMed ID: 19577000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention.
    Yang XJ; Seto E
    Oncogene; 2007 Aug; 26(37):5310-8. PubMed ID: 17694074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylation of proteins as novel target for antitumor therapy: review article.
    Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
    Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis.
    Sun WJ; Zhou X; Zheng JH; Lu MD; Nie JY; Yang XJ; Zheng ZQ
    Acta Biochim Biophys Sin (Shanghai); 2012 Jan; 44(1):80-91. PubMed ID: 22194016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases.
    Yang XJ
    Nucleic Acids Res; 2004; 32(3):959-76. PubMed ID: 14960713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deacetylation of nonhistone proteins by HDACs and the implications in cancer.
    Peng L; Seto E
    Handb Exp Pharmacol; 2011; 206():39-56. PubMed ID: 21879445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule inhibitors of histone acetyltransferase Tip60.
    Wu J; Wang J; Li M; Yang Y; Wang B; Zheng YG
    Bioorg Chem; 2011 Feb; 39(1):53-8. PubMed ID: 21186043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity.
    Stimson L; Rowlands MG; Newbatt YM; Smith NF; Raynaud FI; Rogers P; Bavetsias V; Gorsuch S; Jarman M; Bannister A; Kouzarides T; McDonald E; Workman P; Aherne GW
    Mol Cancer Ther; 2005 Oct; 4(10):1521-32. PubMed ID: 16227401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.